Is PRCT a good stock to buy? We came across a bullish thesis on PROCEPT BioRobotics Corporation on r/ValueInvesting by mrmrmrj. In this article, we will summarize the bulls’ thesis on PRCT. PROCEPT BioRobotics Corporation’s share was trading at $20.91 as of June 17th.
Master Video/Shutterstock.com
Procept BioRobotics (PRCT) is a high-growth surgical robotics company with rapid revenue scaling and expanding gross margins, with revenues having quadrupled since 2022, indicating early-stage economies of scale similar to leading medtech robotics peers. The company’s current operating base is benchmarked against Intuitive Surgical (ISRG), where ISRG in mid-2006 had crossed roughly a similar ~$300 million revenue threshold, comparable gross margins, and a significantly larger capital base, yet traded through a volatile 9–18x sales multiple range.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
By contrast, PRCT currently trades at approximately 4.5x sales despite growing faster at a similar developmental stage, creating a notable valuation gap relative to historical ISRG execution. If PRCT continues to replicate ISRG’s trajectory, multiple expansion and revenue growth could drive substantial equity upside, with potential ~150% appreciation over a three-year horizon driven by revenue compounding and re-rating. Near-term sentiment is mixed due to management guiding revenue slightly below expectations, although still reflecting ~30% year-over-year growth, which introduces short-term skepticism.
However, forward visibility improves significantly with 2027 revenue guidance pointing to a step-change acceleration that remains underappreciated by analysts, setting up a potential upside surprise cycle. Even in a more conservative scenario where analyst expectations prove accurate, the business is still expected to sustain ~25% annual revenue growth, limiting downside risk given the already compressed valuation multiple. With limited evidence of structural de-rating catalysts absent execution failure, PRCT presents a skewed risk-reward profile where continued robotic surgery adoption, scalable margins, and peer-multiple convergence could collectively re-rate the stock meaningfully higher over time.
Previously, we covered a bullish thesis on Intuitive Surgical, Inc. (ISRG) by Kontra Investment Xchange in December 2024, which highlighted robotic surgery leadership, da Vinci system growth, and expanding procedure volumes. ISRG’s stock price has depreciated by approximately 25.79% since our coverage. mrmrmrj shares a similar view but emphasizes valuation gap versus PROCEPT BioRobotics and faster early-stage growth, but differ in maturity and valuation framing.
PROCEPT BioRobotics Corporation is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 28 hedge fund portfolios held PRCT at the end of the first quarter which was 26 in the previous quarter. While we acknowledge the risk and potential of PRCT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PRCT and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
